Zydus Lifesciences (ZYDUSLIFE.NS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $11.63B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IN | CEO | Sharvil Patel |
| IPO Date | 2002-07-01 | CAGR | 15.25% |
| Employees | 29,980 | Website | www.zyduscadila.com |
| Div. Yield | 0.09% | Payout Ratio | 25% |
| Buy Back Yield | — | Total Yield | 0.09% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $11.49B | P/E | 26.12 | Forward P/E | 22.8 | PEG | -0.7 |
| P/S | 3.87 | P/B | 4.12 | P/CF | 117.99 | P/FCF | 1411.04 |
| Sales | $2.99B | Sales 1Y | 21.11% | Sales 3Y | 56.2% | Sales 5Y | 86.74% |
| EPS | $0.45 | EPS 1Y | -1.28% | EPS 3Y | 79.84% | EPS 5Y | 98.63% |
| Sales QoQ | 5.67% | EPS QoQ | -26.09% | Sales QoQ Avg | 5.36% | EPS QoQ Avg | -8.84% |
| Gross Margin | 50.17% | Operating Margin | 18.58% | Profit Margin | 15.78% | ROCE | 14.47% |
| ROA | 9% | ROE | 17% | Altman Z Score | 4.78 | Piotroski Score | 4 |
| Current Ratio | 1.27 | Quick Ratio | 0.91 | Cash Ratio | 0.09 | Op. CF Ratio | — |
| Debt/Equity | 0.46 | Debt/Assets | 0.24 | Lt Debt/Equity | 0.14 | Lt Debt/Cap. | 0.11 |
| Intrst Cov. | 10.41 | Inventory Turnover | 2.53 | Asset Turnover | 0.55 | Receivables Turnover | 5.28 |
| Enterprise Value | $11.49B | P/E Ratio | 26.12 |
| Forward P/E | 22.8 | PEG Ratio | -0.7 |
| P/S Ratio | 3.87 | P/B Ratio | 4.12 |
| P/CF Ratio | 117.99 | P/FCF Ratio | 1411.04 |
| EPS | $0.45 | EPS Growth 1Y | -1.28% |
| EPS Growth 3Y | 79.84% | EPS Growth 5Y | 98.63% |
| Revenue Growth 1Y | 21.11% | Gross Margin | 0.5% |
| Operating Margin | 0.19% | Profit Margin | 0.16% |
| ROE | 0.17% | ROA | 0.09% |
| ROCE | 0.14% | Current Ratio | 1.27 |
| Quick Ratio | 0.91 | Cash Ratio | 0.09 |
| Debt/Equity | 0.46 | Interest Coverage | 10.41 |
| Altman Z Score | 4.78 | Piotroski Score | 4 |
Zydus Lifesciences (ZYDUSLIFE.NS) valuation & financials
Zydus Lifesciences (ZYDUSLIFE.NS) has a market capitalization of 11.63B INR and trades at a price-to-earnings ratio of 26.1. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Zydus Lifesciences's revenue grew +21.1% over the last year.
Zydus Lifesciences's next earnings report is scheduled for November 14, 2026; analysts estimate EPS of 0.08 INR. Check the earnings calendar to see all companies reporting this week.
Zydus Lifesciences (ZYDUSLIFE.NS) — frequently asked questions
When does Zydus Lifesciences (ZYDUSLIFE.NS) report earnings next?
Zydus Lifesciences is expected to report earnings on November 14, 2026. Analysts estimate EPS of 0.08 INR.
What is Zydus Lifesciences's market cap?
Zydus Lifesciences (ZYDUSLIFE.NS) has a market capitalization of 11.63B INR.
What is ZYDUSLIFE.NS's P/E ratio?
Zydus Lifesciences trades at a price-to-earnings ratio of 26.1, with trailing twelve-month EPS of 0.45 INR.
How fast is Zydus Lifesciences growing?
Zydus Lifesciences's revenue grew +21.1% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)